Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors

Front Bioeng Biotechnol. 2023 Feb 16:11:1092901. doi: 10.3389/fbioe.2023.1092901. eCollection 2023.

Abstract

Cancer is a major cause of human death all over the world. Traditional cancer treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and hormone therapy. Although these conventional treatment methods improve the overall survival rate, there are some problems, such as easy recurrence, poor treatment, and great side effects. Targeted therapy of tumors is a hot research topic at present. Nanomaterials are essential carriers of targeted drug delivery, and nucleic acid aptamers have become one of the most important targets for targeted tumor therapy because of their high stability, high affinity, and high selectivity. At present, aptamer-functionalized nanomaterials (AFNs), which combine the unique selective recognition characteristics of aptamers with the high-loading performance of nanomaterials, have been widely studied in the field of targeted tumor therapy. Based on the reported application of AFNs in the biomedical field, we introduce the characteristics of aptamer and nanomaterials, and the advantages of AFNs first. Then introduce the conventional treatment methods for glioma, oral cancer, lung cancer, breast cancer, liver cancer, colon cancer, pancreatic cancer, ovarian cancer, and prostate cancer, and the application of AFNs in targeted therapy of these tumors. Finally, we discuss the progress and challenges of AFNs in this field.

Keywords: aptamer; drug delivery; nanomaterials; targeting therapeutics; tumours.

Publication types

  • Review

Grants and funding

The work was supported by the Zhejiang Province Public Welfare Technology Application Social Development Field Project (LGF20H180008), Zhejiang Provincial Natural Science Foundation General Project (LY16H180006), Zhejiang Provincial Medical and Health Science and Technology Program-Platform Program (2019ZD022 and 2018KY170), and the Zhejiang Health and Health Science and Technology Program (2022KY1304).